BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37890492)

  • 1. Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers.
    Jiagge E; Jin DX; Newberg JY; Perea-Chamblee T; Pekala KR; Fong C; Waters M; Ma D; Dei-Adomakoh Y; Erb G; Arora KS; Maund SL; Njiraini N; Ntekim A; Kim S; Bai X; Thomas M; van Eeden R; Hegde P; Jee J; Chakravarty D; Schultz N; Berger MF; Frampton GM; Sokol ES; Carrot-Zhang J
    Cancer Cell; 2023 Nov; 41(11):1963-1971.e3. PubMed ID: 37890492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology.
    Adib E; Nassar AH; Abou Alaiwi S; Groha S; Akl EW; Sholl LM; Michael KS; Awad MM; Jӓnne PA; Gusev A; Kwiatkowski DJ
    Genome Med; 2022 Apr; 14(1):39. PubMed ID: 35428358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
    Mack PC; Klein MI; Ayers KL; Zhou X; Guin S; Fink M; Rossi M; Ai-Kateb H; O'Connell T; Hantash FM; Oh WK; Newman S; Schadt EE; Chen R; Hirsch FR
    Oncologist; 2022 Jun; 27(6):476-486. PubMed ID: 35298662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
    Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
    J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Genomics of Colorectal Cancer in Populations with African and European Ancestry.
    Myer PA; Lee JK; Madison RW; Pradhan K; Newberg JY; Isasi CR; Klempner SJ; Frampton GM; Ross JS; Venstrom JM; Schrock AB; Das S; Augenlicht L; Verma A; Greally JM; Raj SM; Goel S; Ali SM
    Cancer Discov; 2022 May; 12(5):1282-1293. PubMed ID: 35176763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique Genomic Alterations and Microbial Profiles Identified in Patients With Gastric Cancer of African, European, and Asian Ancestry: A Novel Path for Precision Oncology.
    Abate M; Walch H; Arora K; Vanderbilt CM; Fei T; Drebin H; Shimada S; Maio A; Kemel Y; Stadler ZK; Schmeltz J; Sihag S; Ku GY; Gu P; Tang L; Vardhana S; Berger MF; Brennan MF; Schultz ND; Strong VE
    Ann Surg; 2023 Oct; 278(4):506-518. PubMed ID: 37436885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
    Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
    J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
    Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
    Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
    Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
    J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.
    Sacher AG; Dahlberg SE; Heng J; Mach S; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Mar; 2(3):313-20. PubMed ID: 26720421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.
    Cui W; Franchini F; Alexander M; Officer A; Wong HL; IJzerman M; Desai J; Solomon BJ
    Lung Cancer; 2020 Aug; 146():310-317. PubMed ID: 32619782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF; Chen XY; Yu XB
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients.
    Glaser M; Rasokat A; Prang D; Nogova L; Wömpner C; Schmitz J; Bitter E; Terjung I; Eisert A; Fischer R; John F; von Levetzow C; Michels S; Riedel R; Ruge L; Scharpenseel H; Siebolts U; Merkelbach-Bruse S; Buettner R; Brägelmann J; Wolf J; Scheffler M
    Lung Cancer; 2023 Oct; 184():107344. PubMed ID: 37579577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.
    Lee B; Lee T; Lee SH; Choi YL; Han J
    Oncotarget; 2016 Apr; 7(17):23874-84. PubMed ID: 26992209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations.
    Chen YF; Hsieh MS; Wu SG; Chang YL; Shih JY; Liu YN; Tsai MF; Tsai TH; Yu CJ; Yang JC; Yang PC
    J Thorac Oncol; 2014 Aug; 9(8):1171-9. PubMed ID: 25157770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations.
    Leal LF; de Paula FE; De Marchi P; de Souza Viana L; Pinto GDJ; Carlos CD; Berardinelli GN; Miziara JE; da Silva CM; Silva ECA; Pereira R; de Oliveira MA; Scapulatempo-Neto C; Reis RM
    Sci Rep; 2019 Mar; 9(1):3209. PubMed ID: 30824880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients.
    Li D; Jiang H; Jin F; Pan L; Xie Y; Zhang L; Li C
    Genes Genomics; 2023 Jan; 45(1):93-102. PubMed ID: 36445572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer.
    Liu X; Li G; Zhang H; Chang Q; Fang M; Lu C; Tian P; Mei F
    Clin Neurol Neurosurg; 2023 Feb; 225():107572. PubMed ID: 36610238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.